US 10,689,357 B2 · N-acylethanolamine hydrolyzing acid amidase (NAAA) inhibitors and use thereof

Abstract

Disclosed herein are compounds represented by Structural Formula I: or a pharmaceutically acceptable salt thereof. Values for the variables in Structural Formula I are described herein. The compounds can be used to modulate (e.g., inhibit) N-acylethanolamine hydrolyzing acid amidase (NAAA) and thereby treat a variety of diseases, disorders and conditions mediated by NAAA, such as a gastrointestinal motility disorder, irritable bowel syndrome, an inflammatory bowel disorder, neuroinflammation, nicotine addiction, cancer, opioid dependence, analgesia, chemotherapy-induced neuropathic pain and pain. Also disclosed herein are compositions and methods including compounds of Structural Formula I, or a pharmaceutically acceptable salt thereof.

Claims18

Dependent claims

A compound represented by the following structural formula:

or a pharmaceutically acceptable salt thereof, wherein:
Ring A is absent, cycloalkyl, aryl, heterocyclyl or heteroaryl;
V is absent, —O—, —N(R10)—, —S(O)2—, —S(O)—, —C(O)—, —C(O)N(R10)— or —C(R11)(R12);
R10 is —H or C1-C4 alkyl;
R11 and R12 are each independently —H, C1-C4 alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl, or taken together with the carbon atom to which they are attached, form a saturated or unsaturated ring;
B is C1-C6 alkylene, C1-C6 alkenylene, C1-C6 alkynylene, cycloalkylene, arylene, heterocyclylene or heteroarylene;
Y is —C(O)N(R13)—, —C(O)O—, —S(O2)N(R13)—, —S(O2)O—, —P(O)(R14)N(R13)—, —P(O)(R14)O—, —OC(O)N(R13)—, —OC(O)O— or —N(R13)C(O)N(R13)—;
each R13 is independently —H or C1-C4 alkyl;
R14 is C1-C4 alkyl;
and
Ring D is C3-C7 cycloalkyl.

8 more elements

Dependencies are inferred from the claim text.

N-acylethanolamine hydrolyzing acid amidase (NAAA) inhibitors and use thereof

Life of this patent

N-acylethanolamine hydrolyzing acid amidase (NAAA) inhibitors and use thereof

Life of this patent

Abstract

Claims18